Abstract:Depression has severely impaired the health of the people all over the world. Cognitive dysfunction due to depression has exerted serious economic burden to family and society induced by the reduction of social functioning for patients. NDRIs targeted with norepinephrine transport (hNET) and distribution than dopamine transport (hDAT) simultaneously treat depression and improve cognitive function, and they effectively avoid sexual dysfunction and other side effects. However, the drugs of NDIRs are still performing poor response to many patients. So it is urgent to discover novel NDRIs antidepressants with the ability of improving the cognitive fuction. The aim of this work was to identify novel NDRIs candicates selectively against hNET and hDAT from large compound libraries by comprehensive strategy integrating SVM, ADME/T, molecular docking, vitro binding assays, molecular dynamics simulation and binding energy calculation. Firstly, 6,522 compounds without inhibiting serotonin transporter (hSERT) were hitted by SVM models of hNET, hDAT and non-target hSERT with similarities analysis from compound libraries. ADME/T and molecular docking were then used to filter compounds which could potently bind in hNET and hDAT with good ADME/T, and 4 compounds were successfully identified. According to their docking scors and ADME/T information, 3719810 was advanced for profiling in vitro assays as novel NDRIs lead compound attributing to its best druggability and balance activities. Encouragingly, 3719810 performed comparative activities on two targets with Ki value 7.32 μM for hNET and 5.23μM for hDAT. In order to abtain candicates with more activities and balance activities of 2 targets, 5 analogs were optimized and 2 novel scaffold compounds were successively designed. By assessment of molecular docking, molecular dynamics simulation and binding energy calculation, 5 compounds were validated as NDRIs candicates with high activties, and 4 out of them performed acceptable balance actives acting on hNET and hDAT, which could supply promising novel NDRIs to exploit drugs for depression with cognitive dysfunction or other related neruodegenrative disorders, and also shed sight on screening inhibitors for dual-target with homological non-target on highly efficient and cost-effective.

Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity.

Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.

Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/H3 Agents: Synthesis and Biological Evaluation

Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a Novel Triple Serotonin, Norepinephrine and Dopamine Reuptake Inhibitor

Discovery of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists Containing an Isoxazolylpyridine Ether Scaffold That Demonstrate Antidepressant-like Activity. Part II

Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants

Exploration of 1-(4-(7-Azaindole)-3,6-dihydropyridin-1-yl)alkyl-3-(1H-indol-3-yl)pyrrolidine-2,5-dione Derivatives with Affinity for the Serotonin Transporter

Further Studies on Conformationally Constrained Tricyclic Tropane Analogues and Their Uptake Inhibition at Monoamine Transporter Sites: Synthesis of (Z)-9-(substituted Arylmethylene)-7-azatricyclo[4.3.1.03,7]decanes As a Novel Class of Serotonin Transporter Inhibitors

Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.

Discovery of Novel and Potent <i>N</i>-Methyl-D-aspartate Receptor Positive Allosteric Modulators with Antidepressant-like Activity in Rodent Models

A Multiple-step Screening Protocol to Identify Norepinephrine and Dopamine Reuptake Inhibitors for Depression

Synthesis and biological evaluation of multimodal monoaminergic arylpiperazine derivatives with potential antidepressant profile

Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template

Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter

Development of MAO-A and 5-HT2AR Dual Inhibitors with Improved Antidepressant Activity.

Involvement of Organic Cation Transporter 2 Inhibition in Potential Mechanisms of Antidepressant Action

Stereochemical optimization of N,2-substituted cycloalkylamines as norepinephrine reuptake inhibitors

Discovery of Isoxazole Analogues of Sazetidine-A As Selective Α4β2-Nicotinic Acetylcholine Receptor Partial Agonists for the Treatment of Depression

Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.

Thiophene Derivatives: a New Series of Potent Norepinephrine and Serotonin Reuptake Inhibitors

Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity